#Liver2013 poster 1092 12 wks of Simeprevir/P/R +12 wks of PR cures 70% G1a relapsers but cure rate only 47% if Q80K mutation present (12%)
December 3, 2024 at 3:13 PM
#Liver2013 poster 1092 12 wks of Simeprevir/P/R +12 wks of PR cures 70% G1a relapsers but cure rate only 47% if Q80K mutation present (12%)
#liver2013 Hepatitis debrief: Dr. Sulkowski ?need Q80K testing if considering simeprevir/rare virological failure via S282T with sofosbuvir
December 3, 2024 at 3:03 PM
#liver2013 Hepatitis debrief: Dr. Sulkowski ?need Q80K testing if considering simeprevir/rare virological failure via S282T with sofosbuvir
Personally familiar, given I'm a survivor of HCV 1A, Q80k.
IME House reports more recently appear about celebrating or chastising past efforts to set a basis for future funding or policy. Among other things the report is likely laying the groundwork to justify future travel bans.
IME House reports more recently appear about celebrating or chastising past efforts to set a basis for future funding or policy. Among other things the report is likely laying the groundwork to justify future travel bans.
December 9, 2024 at 9:23 PM
Personally familiar, given I'm a survivor of HCV 1A, Q80k.
IME House reports more recently appear about celebrating or chastising past efforts to set a basis for future funding or policy. Among other things the report is likely laying the groundwork to justify future travel bans.
IME House reports more recently appear about celebrating or chastising past efforts to set a basis for future funding or policy. Among other things the report is likely laying the groundwork to justify future travel bans.
For example, subclade K viruses with the Q80K HA site E substitution have been detected at relatively high frequencies in some parts of the world, and it is unclear if future subclade K vaccine strains with an Q80 or K80 HA should be selected for the 2026-2027 influenza season. 5/
February 22, 2026 at 4:14 PM
For example, subclade K viruses with the Q80K HA site E substitution have been detected at relatively high frequencies in some parts of the world, and it is unclear if future subclade K vaccine strains with an Q80 or K80 HA should be selected for the 2026-2027 influenza season. 5/